Built for Success at Scale: Inside Simtra's Integrated CDMO ModelByRich Kennedy, Simtra BioPharma SolutionsJuly 23rd 2026Sponsored
What It Takes to Support Emerging Biopharma Programs Through Rapid Candidate IdentificationByLaura Daley, PhD, Catalent Pharma Solutions,Jeanne Linke Northrop, BioPharm InternationalJune 17th 2026Sponsored
Expanding CDMO Capabilities in Drug ManufacturingByNuno Fontes, SVP, Head of Global CMC,WuXi BiologicsMay 14th 2026Sponsored
How Biologic Developers are Using Optimized Platforms and Operations to Reach First-in-Human TrialsByEmily Schirmer, Catalent,Jeanne Linke Northrop, BioPharm InternationalMay 13th 2026Sponsored
Choosing the Right CDMO for Long-Term StabilityByDr. Patrick Meyer, Global Head of Business Development,Rentschler BiopharmaPublished: May 4th 2026 | Updated: May 4th 2026Sponsored
